Graham P E, Smythe G A, Edwards G A, Lazarus L
Department of Chemical Pathology, St Vincent's Hospital, Darlinghurst, NSW, Australia.
Ann Clin Biochem. 1993 Mar;30 ( Pt 2):129-34. doi: 10.1177/000456329303000203.
There is a diversity of advice in the literature as to which biochemical assays are best suited to the investigation of patients with a suspected phaeochromocytoma. The challenge for the clinical laboratory is to select those assays which detect all phaeochromocytomas, whilst having the lowest incidence of false positive diagnoses. We compared the sensitivity and specificity of a wide range of assays currently used for the biochemical diagnosis of phaeochromocytoma using either specific gas chromatographic-mass spectrometric (GC/MS) or high performance liquid chromatography-electrochemical detection (HPLC/ED) techniques. Noradrenaline (NA), adrenaline (ADR), dopamine (DA), 3,4-dihydroxyphenylglycol (DHPG), hydroxymethoxymandelic acid (HMMA), normetanephrine (NMET) and metanephrine (MET) were measured in 24 h urine specimens from 20 patients with histologically proven phaeochromocytoma and a large group of patients referred for investigation but subsequently found not to have a phaeochromocytoma. Because phaeochromocytomas are a heterogeneous group of hormone secreting tumours, no single analyte could achieve 100% sensitivity; 100% sensitivity was achieved only when the combination of both NA and ADR or NMET and MET was used. DA, DHPG and HMMA all had poor sensitivities. HMMA had a sensitivity of 70% when using the upper 95% confidence level (48 mumol/24 h) of the non-tumour patients as the cut-off. By lowering the cut-off to 35 mumol/24 h the sensitivity could be increased to 100% but at the expense of the specificity which was decreased from 98 to 92%. On the basis of this study we recommend the specific measurement of either NA and ADR or NMET and MET as the most suitable analytes for the detection of phaeochromocytoma, and further that, due to its poor specificity, HMMA be abandoned as a suitable analyte.
关于哪些生化检测最适合用于疑似嗜铬细胞瘤患者的检查,文献中有各种各样的建议。临床实验室面临的挑战是选择那些能够检测出所有嗜铬细胞瘤,同时假阳性诊断发生率最低的检测方法。我们使用特定的气相色谱 - 质谱联用(GC/MS)或高效液相色谱 - 电化学检测(HPLC/ED)技术,比较了目前用于嗜铬细胞瘤生化诊断的多种检测方法的灵敏度和特异性。在20例经组织学证实为嗜铬细胞瘤的患者以及一大组被转诊进行检查但随后发现没有嗜铬细胞瘤的患者的24小时尿液样本中,检测了去甲肾上腺素(NA)、肾上腺素(ADR)、多巴胺(DA)、3,4 - 二羟基苯乙二醇(DHPG)、羟甲氧基扁桃酸(HMMA)、去甲变肾上腺素(NMET)和变肾上腺素(MET)。由于嗜铬细胞瘤是一组异质性的激素分泌肿瘤,没有单一分析物能够达到100%的灵敏度;只有当使用NA和ADR或NMET和MET的组合时,才能达到100%的灵敏度。DA、DHPG和HMMA的灵敏度都很差。当以非肿瘤患者的95%置信区间上限(48 μmol/24 h)作为临界值时,HMMA的灵敏度为70%。通过将临界值降低到35 μmol/24 h,灵敏度可以提高到100%,但特异性会从98%降至92%。基于这项研究,我们建议特异性检测NA和ADR或NMET和MET作为检测嗜铬细胞瘤最合适的分析物,并且进一步建议,由于其特异性较差,应放弃将HMMA作为合适的分析物。